Nexstim (NXTMH) H1 2026 earnings summary

Executive summary

• Net sales grew 16.1% year-over-year to EUR 5.2 million, driven by strong research and neuroscience business performance and recurring and licensing revenue growth.

• Recurring revenue accounted for 48% of net sales, with gross margin at 80%.

• Strategic partnerships with Brainlab and Sinaptica advanced, supporting expansion in neurosurgery and Alzheimer's therapy markets.

• Maintained technology leadership with FDA and CE approvals for the NBS 6 platform across diagnostics, therapy, and research.

• EUR 5 million investment from Eiffel Investment Group and Brainlab SE strengthened the balance sheet and supports growth strategy.

Financial highlights

• Group revenue rose to EUR 5.2 million from EUR 4.5 million in H1 2025.

• Gross margin increased 15% year-over-year to EUR 4.2 million, maintaining an 80% margin ratio.

• EBITDA improved by nearly 10% to EUR 0.3 million; fourth consecutive half-year with positive EBITDA.

• Operating profit was EUR -0.3 million; net profit EUR -0.9 million, impacted by EUR 0.6 million in one-off financing expenses.

• Cash and cash equivalents more than doubled to EUR 5.6 million; equity ratio improved to over 61%.

Outlook and guidance

• Guidance for 2026 unchanged: net sales expected to grow and operating result to improve.

• Focus remains on profitable growth, expanding recurring revenue, and leveraging strategic partnerships and technology leadership.